For drug response assessments, the threshold at which c-Myc switches from supporting cell survival to inducing irreversible cell cycle arrest in relation to ErbB2 levels could inform the development of more effective molecular-targeted treatment strategies for breast cancer. The gene discussed is MYC; the disease is breast carcinoma.